Plate Market Review:
This week (1.3 ~ 1.7), Shenwan beauty care sector – 5.41%. The Shanghai Composite Index and the gem index were – 1.65% and – 6.80% respectively. Shenwan beauty care sector lost 3.76 PCT to the Shanghai Composite Index and outperformed the gem index by 1.39 PCT.
Wind medical beauty and cosmetics index: this week, the CSI 300 index was – 2.39%, and the wind medical beauty index was – 4.95%, underperforming the CSI 300 market by 2.56pct; The wind cosmetics index was – 2.95%, underperforming the CSI 300 market by 0.56pct.
Industry highlights:
The State Food and Drug Administration (SFDA) issued the quality management specification for cosmetics production, which stipulates all aspects of the production and operation of cosmetics related enterprises, such as the establishment of a quality and safety person in charge, the establishment and improvement of cosmetics production quality management system documents, etc. The specification will take effect on July 1, 2022. If the cosmetics production license has been obtained, but the plant equipment and other hardware facilities do not meet the requirements, the upgrading and transformation must be completed before July 1, 2023. (State Drug Administration)
Company announcement:
Lushang Health Industry Development Co.Ltd(600223) : (1) the exercise conditions for the second exercise period of the reserved grant part of the company’s 2018 stock option incentive plan have been met. Except for those who lose the exercise qualification of the stock option incentive plan due to resignation and other reasons, the reserved grant incentive objects for this exercise are 53, the number of exercisable stock options is 302900, and the exercise price is 3.22 yuan / share.
(2) with the approval of the general meeting of shareholders of the company, the expected guarantee amount of the company in 2021 is 5 billion yuan. As of the disclosure date of this announcement, the external guarantees of the company and wholly-owned companies and holding companies at all levels are guarantees for wholly-owned companies and holding companies, or between them, and there is no guarantee for a third party.
Bloomage Biotechnology Corporation Limited(688363) : the board of directors of the company recently received a written resignation report from Mr. Li Huiliang, deputy general manager, chief technical officer and core technician of the company. He resigned as deputy general manager and chief technical officer of the company for personal reasons and will no longer serve as a core technician. After his resignation, he will no longer hold any position in the company and its subsidiaries.
Investment advice
(1) cosmetics industry: the State Food and Drug Administration issued the quality management specification for cosmetics production, supervised the whole process of product production, put forward higher requirements for cosmetics production equipment and production environment, and increased the threshold for the entry of new brands. We are optimistic about head cosmetics enterprises with complete plant equipment and strict production process control. Focus on: [ Yunnan Botanee Bio-Technology Group Co.Ltd(300957) ] subdivide the leaders in the field of sensitive muscle skin care; [ Proya Cosmetics Co.Ltd(603605) ] diversified high-quality brands; [ Shanghai Jahwa United Co.Ltd(600315) ] multi category development and continuous innovation to create new items; [ Guangdong Marubi Biotechnology Co.Ltd(603983) ] mainly focuses on medium and high-end, with rich marketing and distribution channels; [ Syoung Group Co.Ltd(300740) ] strong operation capacity and gradual improvement of category structure;
(2) medical beauty industry: the demand side of the medical beauty industry continues to expand, the supply side products are more diversified, and the policy side strengthens the supervision of medical beauty institutions and medical beauty products. We are optimistic about upstream medical and American enterprises with class III medical device certificate and perfect product matrix layout and downstream medical institutions with long-term standardized operation. Attention: [ Bloomage Biotechnology Corporation Limited(688363) ] local hyaluronic acid raw material leader; [ Imeik Technology Development Co.Ltd(300896) ] Tongyan needle is heavily listed and differentiated to meet higher needs; [ Huadong Medicine Co.Ltd(000963) ] overall layout of medical and American business; [ Shanghai Haohai Biological Technology Co.Ltd(688366) ] integration of R & D, production and sales; [tetracyclic medicine] botulinum toxin + double antibody go hand in hand; Pay attention to Lancy Co.Ltd(002612) and so on.
Risk tips
Risk of intensified industry competition; Uncertainty of industry regulatory policies; Macroeconomic fluctuations, etc.
